The ICH S1B guidance is making significant ripples across our industry, potentially saving years of effort in the development of a new drug, and SEND can play its part in enabling this.
The proliferation of standardized nonclinical data has paved the way for us to explore new ways to reuse and repurpose existing study data.
AI has clear uses in fraud detection, cybersecurity, and supply chain management, and seems to be used in innovative applications across various industries but does it have an application for SEND?
Due to be published in 2026, SEND 4.0 is the next update due for the SEND standard.
In this ever-evolving ecosystem, the key to unlocking a future rich in insights and possibilities is to harness the power of the data cycle.
Aside from implementation of the Genetox IG, the other main activity that is currently advancing is SEND v4.0.
